Amiodarone and thyroid status in refractory arrhythmias

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Refractory arrhythmias pose a significant clinical challenge.
• Amiodarone is an effective antiarrhythmic but carries risks of side effects.
• Understanding amiodarone's impact on thyroid hormone levels is crucial for safe usage.

Purpose of the Study:

• To evaluate the efficacy and safety of low-dose amiodarone (200 mg/day) in patients with refractory arrhythmias.
• To investigate the effects of amiodarone on thyroid hormone profiles.
• To explore potential biomarkers for therapeutic monitoring and side effect prediction.

Main Methods:

• Prospective study of 20 patients with refractory arrhythmias receiving amiodarone 200 mg/day.
• Assessment of electrocardiographic parameters (QTc) and clinical side effects at 1 year.
• Measurement of circulating amiodarone levels and thyroid hormones (rT3, TT3, FT3, FT4).

Main Results:

• 85% of patients achieved therapeutic efficacy.
• No statistically significant changes in QTc interval or significant side effects were observed.
• Amiodarone induced a "Low T3 Syndrome" characterized by increased rT3 and decreased TT3, with stable FT3/FT4.
• Circulating amiodarone levels were not reliable for monitoring in borderline thyroid states.
• A significant linear relationship was found between cumulative amiodarone dose and rT3 levels.

Conclusions:

• Low-dose amiodarone (200 mg/day) is effective and safe for refractory arrhythmias.
• The observed "Low T3 Syndrome" pattern is associated with this low-dose regimen.
• Monitoring rT3 levels may aid in optimizing amiodarone dosage and predicting side effects, with a suggested threshold of 100-110 ng/dl.